ifosfamide has been researched along with Pancreatic Neoplasms in 44 studies
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine." | 9.14 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. ( Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT, 2009) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 7.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 7.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide." | 7.67 | Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. ( Ansari, R; Einhorn, LH; Loehrer, PJ; Williams, SD, 1985) |
| " Alternative dosing of glufosfamide plus gemcitabine should be explored." | 6.75 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ( Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT, 2010) |
| "To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination with gemcitabine in advanced solid tumors." | 6.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| "There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine." | 5.14 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. ( Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT, 2009) |
| "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%." | 3.69 | Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 3.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide." | 3.67 | Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. ( Ansari, R; Einhorn, LH; Loehrer, PJ; Williams, SD, 1985) |
| " Alternative dosing of glufosfamide plus gemcitabine should be explored." | 2.75 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. ( Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT, 2010) |
| "To evaluate safety and pharmacokinetics and to establish the maximum tolerated dose of glufosfamide when administered in combination with gemcitabine in advanced solid tumors." | 2.73 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. ( Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF, 2008) |
| "Intraperitoneal carcinomatosis (PC) may occur with several tumor entities." | 2.49 | Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. ( Binder, S; Keese, M; Lewis, AL; Löhr, JM, 2013) |
| "Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour." | 2.43 | Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer. ( Günzburg, WH; Salmons, B, 2005) |
| "Patients with pancreatic cancer are treated with combined treatment modalities." | 2.42 | [The update on pancreatic cancer chemotherapy]. ( Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E, 2003) |
| "Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | 1.72 | Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Local therapy of pancreatic cancer with microencapsulated CYP2B1-producing cells and ifosfamide showed an effect both on the primary tumor and on distant metastatases." | 1.33 | Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation. ( Engel, A; Fabian, OV; Harms, W; Jesnowski, R; Löhr, M; Ringel, J; Ryschich, E; Saller, R; Schmidt, J; Schrewe, M, 2005) |
| "Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma." | 1.30 | [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma]. ( Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Suda, Y; Terashi, K; Yamamoto, K; Yamato, A, 1997) |
| "The prognosis of pancreatic cancer is poor, and current medical treatment is mostly ineffective." | 1.30 | Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. ( Günzburg, WH; Jesnowski, R; Karle, P; Liebe, S; Löhr, M; Müller, P; Nizze, H; Püschel, K; Renz, R; Saller, R; Salmons, B; Stein, H; von Rombs, K; Wagner, T, 1999) |
| " We have studied in patients with advanced cancer the feasibility and bioavailability of a subcutaneously administered isotonic and neutral (pH 7) IFO solution given continuously over 10 h for up to 5 days." | 1.28 | Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. ( Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T, 1990) |
| "Ifosfamide was studied in advanced pancreatic tumor at the National Cancer Institute, Cairo." | 1.27 | Ifosfamide in advanced pancreatic cancer. A 5-year experience. ( Gad-el-Mawla, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (20.45) | 18.7374 |
| 1990's | 14 (31.82) | 18.2507 |
| 2000's | 14 (31.82) | 29.6817 |
| 2010's | 5 (11.36) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, YC | 3 |
| Yeh, TC | 3 |
| Wu, PS | 3 |
| Sheu, JC | 3 |
| Lee, HC | 3 |
| Yeung, CY | 3 |
| Jiang, CB | 3 |
| Liu, HC | 3 |
| Hou, JY | 3 |
| Chan, WT | 3 |
| Yonemaru, J | 1 |
| Takahashi, M | 1 |
| Nara, S | 1 |
| Ichikawa, H | 1 |
| Ishigamori, R | 1 |
| Imai, T | 1 |
| Hiraoka, N | 1 |
| Paasch, C | 1 |
| De Santo, G | 1 |
| Boettge, KR | 1 |
| Strik, MW | 1 |
| Binder, S | 1 |
| Lewis, AL | 1 |
| Löhr, JM | 1 |
| Keese, M | 1 |
| Ciuleanu, TE | 1 |
| Pavlovsky, AV | 1 |
| Bodoky, G | 1 |
| Garin, AM | 1 |
| Langmuir, VK | 3 |
| Kroll, S | 3 |
| Tidmarsh, GT | 2 |
| Chiorean, EG | 2 |
| Dragovich, T | 2 |
| Hamm, J | 2 |
| Barrios, CH | 1 |
| Gorini, CF | 1 |
| Jung, DT | 2 |
| Loehrer, PJ | 6 |
| Cereda, S | 1 |
| Reni, M | 1 |
| Rognone, A | 1 |
| Fugazza, C | 1 |
| Ghidini, M | 1 |
| Ceraulo, D | 1 |
| Brioschi, M | 1 |
| Nicoletti, R | 1 |
| Villa, E | 1 |
| Hlavaty, J | 1 |
| Petznek, H | 1 |
| Holzmüller, H | 1 |
| Url, A | 1 |
| Jandl, G | 1 |
| Berger, A | 1 |
| Salmons, B | 11 |
| Günzburg, WH | 11 |
| Renner, M | 4 |
| Löhr, M | 8 |
| Briasoulis, E | 1 |
| Pavlidis, N | 1 |
| Terret, C | 1 |
| Bauer, J | 1 |
| Fiedler, W | 1 |
| Schöffski, P | 1 |
| Raoul, JL | 1 |
| Hess, D | 1 |
| Selvais, R | 1 |
| Lacombe, D | 1 |
| Bachmann, P | 1 |
| Fumoleau, P | 1 |
| Brasiūniene, B | 1 |
| Juozaityte, E | 1 |
| Brasiūnas, V | 1 |
| Inciūra, A | 1 |
| Ryschich, E | 1 |
| Jesnowski, R | 5 |
| Ringel, J | 2 |
| Harms, W | 1 |
| Fabian, OV | 1 |
| Saller, R | 5 |
| Schrewe, M | 1 |
| Engel, A | 1 |
| Schmidt, J | 1 |
| Bendell, JC | 1 |
| Lauwers, GY | 1 |
| Willett, C | 1 |
| Clark, JW | 1 |
| Warshaw, AL | 1 |
| Wain, JC | 1 |
| Ryan, DP | 1 |
| Colowick, AB | 1 |
| Tidmarsh, GF | 2 |
| Ammons, WS | 1 |
| Wang, JW | 1 |
| Yang, Z | 1 |
| Hoffman, RM | 1 |
| Schäfer, HS | 1 |
| Becker, H | 1 |
| Schmitt-Gräff, A | 1 |
| Lübbert, M | 1 |
| Holoye, PY | 1 |
| Anderson, T | 1 |
| Duelge, J | 1 |
| Hansen, RM | 1 |
| Ritch, PS | 1 |
| Williams, SD | 3 |
| Einhorn, LH | 3 |
| Wils, JA | 1 |
| Kok, T | 1 |
| Wagener, DJ | 1 |
| Francois, E | 1 |
| Selleslags, J | 1 |
| Duez, N | 2 |
| Di Costanzo, F | 1 |
| Tagliaventi, M | 1 |
| Carlini, P | 1 |
| Zironi, S | 1 |
| Mazzocchi, B | 1 |
| Bella, M | 1 |
| Donati, D | 1 |
| Acito, L | 1 |
| Maggian, P | 1 |
| Angiona, S | 1 |
| Wahid, NA | 1 |
| Neugut, AI | 1 |
| Hibshoosh, H | 1 |
| Brunetti, JC | 1 |
| Fountain, KS | 1 |
| Rubin, M | 1 |
| Poorter, RL | 1 |
| Bakker, PJ | 1 |
| Huizing, MT | 1 |
| Taat, CW | 1 |
| Rietbroek, RC | 1 |
| Gouma, DJ | 1 |
| Rauws, EA | 1 |
| Veenhof, CH | 1 |
| Fujiki, T | 1 |
| Futatsuki, K | 1 |
| Akazawa, S | 1 |
| Yamamoto, K | 1 |
| Kanda, Y | 1 |
| Yamato, A | 1 |
| Terashi, K | 1 |
| Suda, Y | 1 |
| Lee, AC | 1 |
| Wong, KW | 1 |
| Cheng, MY | 1 |
| Karle, P | 6 |
| Müller, P | 5 |
| Renz, R | 3 |
| von Rombs, K | 2 |
| Nizze, H | 4 |
| Liebe, S | 5 |
| Stange, J | 1 |
| Mitzner, S | 1 |
| Nebe, B | 1 |
| Bago, ZT | 1 |
| Bergmeister, H | 1 |
| Ceijna, M | 1 |
| Freund, M | 2 |
| Gelbmann, W | 1 |
| Hain, J | 3 |
| Hauenstein, K | 2 |
| Henninger, W | 1 |
| Hoffmeyer, A | 2 |
| Kröger, JC | 1 |
| Kundt, G | 1 |
| Losert, U | 1 |
| Probst, A | 1 |
| Püschel, K | 2 |
| Walter, I | 1 |
| Stein, H | 1 |
| Wagner, T | 2 |
| Kröger, J | 1 |
| Holle, A | 1 |
| Knöfel, WT | 1 |
| Saller, RM | 1 |
| Hummel, F | 1 |
| Faulmann, G | 1 |
| Vannier, JP | 1 |
| Flamant, F | 1 |
| Hemet, J | 1 |
| Caillaud, JM | 1 |
| Gruner, M | 1 |
| Bachy, B | 1 |
| Lefur, R | 1 |
| Lemerle, J | 1 |
| Tron, P | 1 |
| Cerny, T | 2 |
| Martinelli, G | 1 |
| Goldhirsch, A | 1 |
| Terrier, F | 1 |
| Joss, R | 1 |
| Fey, MF | 1 |
| Brunner, KW | 2 |
| Küpfer, A | 2 |
| Abad, A | 1 |
| Rosell, R | 1 |
| Barnadas, A | 1 |
| Carles, J | 1 |
| Ribelles, N | 1 |
| Solano, V | 1 |
| Zeugin, T | 1 |
| Wils, J | 1 |
| Bleiberg, H | 1 |
| Buyse, M | 1 |
| Wagener, DT | 1 |
| Splinter, T | 1 |
| Veenhof, C | 1 |
| Herben, M | 1 |
| Gad-el-Mawla, N | 1 |
| Nichols, CR | 1 |
| Ajani, JA | 1 |
| Abbruzzese, JL | 1 |
| Goudeau, P | 1 |
| Faintuch, JS | 1 |
| Yeomans, AC | 1 |
| Boman, BM | 1 |
| Nicaise, C | 1 |
| Levin, B | 1 |
| Ansari, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and IL2 for Treatment of Advanced Solid Tumors[NCT04770207] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
| Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer[NCT00005053] | Phase 2 | 35 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ifosfamide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell- and Tissue-Based Therapy; Chemoembolization, Therap | 2013 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; | 2005 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Canc | 2001 |
Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Cytochrome P-450 CYP2B1; Drug | 2002 |
14 trials available for ifosfamide and Pancreatic Neoplasms
| Article | Year |
|---|---|
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Deoxycytidine; Fe | 2009 |
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; | 2010 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dis | 2011 |
Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Cell Transplantation; Cytochrome P-450 CYP2B1; Do | 2003 |
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Fema | 2003 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
Phase II trial with ifosfamide in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms | 1993 |
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1996 |
Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study.
Topics: Adult; Aged; Cell Line; Cytochrome P-450 CYP2B1; Drug Compounding; Female; Genetic Therapy; Genetic | 1999 |
Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cell Transplantation; Cytochrome P-450 CYP2B1; Dose- | 2001 |
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfami | 1991 |
Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Ifosfamide; Male; Mercaptoet | 1988 |
25 other studies available for ifosfamide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male; | 2022 |
A yolk sac tumor of the pancreas and derived xenograft model effectively responded to VIP chemotherapy.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cis | 2020 |
Mesenchymal chondrosarcoma metastasising to the pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cholangiopan | 2018 |
Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.
Topics: Animals; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzym | 2012 |
Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Combined Modality Therapy; Cytochrom | 2005 |
Pancreatoblastoma in a teenage patient.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Topics: Alkylating Agents; Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; | 2007 |
Granulocytic sarcoma of Core-binding Factor (CBF) acute myeloid leukemia mimicking pancreatic cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; CA-19-9 Antig | 2008 |
N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1983 |
Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Cy | 1996 |
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 1995 |
[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Huma | 1997 |
"Response to Hord and Janco re chemotherapy for unresectable pancreatoblastoma".
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; A | 1997 |
Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
Topics: Adenocarcinoma; Animals; Biotransformation; Capsules; Cell Line; Cell Survival; Cell Transplantation | 1998 |
Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
Topics: Adenocarcinoma; Animals; Capsules; Cats; Combined Modality Therapy; Cytochrome P-450 CYP2B1; Genetic | 1998 |
Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Capsules; Cell Line; Cytochrome P-450 CYP2B1; Disease Mo | 1999 |
Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cats; Cell Line; Cells, Cultu | 2001 |
Pancreatoblastoma: response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; | 1991 |
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili | 1991 |
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug | 1990 |
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous | 1989 |
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Epirub | 1989 |
Ifosfamide in advanced pancreatic cancer. A 5-year experience.
Topics: Adult; Alopecia; Anemia; Drug Evaluation; Female; Humans; Ifosfamide; Leukopenia; Male; Mesna; Middl | 1986 |
Ifosfamide chemotherapy for pancreatic carcinoma.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam | 1986 |
Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas.
Topics: Acetylcysteine; Adenocarcinoma; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mid | 1985 |